icon
Getting Started
Business and Industry
Lucid News
2024-09-20

Mindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT

Substance Abuse

Anxiety

Stress

Mindstate Design Labs has received approval for a Phase 1 clinical trial to investigate the use of its formulation of 5-MeO-MiPT which it hopes to combine with other drugs to target precise serotonin receptors and create future psychotropic therapies.

Related News

Colorado’s Approach to Psychedelic-Assisted Therapy: An Evolution in Mental Health Care

Elizabeth Nielson, co-founder of Fluence, offers thoughts on the roll out of the 2025 psychedelic therapy program in Colorado and the opportunities it offers for mental health professionals.

Read More icon
The Psychedelic Underground’s Future Is in Consumer Packaged Goods

Let’s not kid ourselves: medical access is merely a stepping stone to legality.

Read More icon
Offshore Ibogaine Clinics In Mexico, Portugal, and Brazil

In part one of a series of articles on ibogaine clinics, researcher Leonard Pickard looks at the history and treatment protocols of clinics in Mexico, Brazil and Portugal.

Read More icon
Companies looking to fund psychedelic drug therapy for employees: report

A growing number of companies are exploring the possibility of offering psychedelic drug therapy for their employees as a cost-saving and effective means of mental health treatment, according to a …

Read More icon
The Church of the Eagle and the Condor Settles with Federal Agencies, Can Continue Importing and Using Ayahuasca

Here, we explore the settlement as well as the potential repercussions for other religious groups that seek to use psychedelics as part of their practices. We also share a response from certain…

Read More icon